Skip to main content
ResearchTreatments

Current Landscape and the New Emerging Therapies in EGFR-positive NSCLC

*November 2023*

This is a very interesting video presentation consisting of lung cancer experts and EGFR Resisters co-founder Jill Feldman discussing the treatment options after osimertinib (Tagrisso) faillure. It covers:

  • Importance of liquid and tissue biopsies to check for new mutations
    • chemo is standard of care
    • amivantamab +lazertinib
    • ADCs
    • clinical trials
  • When considering next treatment: Were drug approvals based on PFS or OS? How will quality of life change?
  • Keeping certain treatments as options in your back pocket for future lines of therapy, rather than aggressively employing multiple combinations in one line of therapy.

Watch video here.